Price$10.19-0.10 (-0.97%)
01:45 PM07:45 PM
News · 26 weeks28-58%
2025-10-262026-04-19
Mix2190d
- Insider9(43%)
- SEC Filings5(24%)
- Other4(19%)
- Earnings3(14%)
Latest news
25 items- INSIDERPresident, CEO Shelton Jerrell exercised 104,007 shares at a strike of $1.87, increasing direct ownership by 9% to 1,230,614 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECSEC Form DEFA14A filed by CryoPort Inc.DEFA14A - Cryoport, Inc. (0001124524) (Filer)
- SECSEC Form DEF 14A filed by CryoPort Inc.DEF 14A - Cryoport, Inc. (0001124524) (Filer)
- PRCryoport to Report First Quarter 2026 Financial Results on May 4, 2026NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the first quarter ended March 31, 2026 on Monday, May 4, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2026 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued
- INSIDERSEC Form 4 filed by Shelton Jerrell4 - Cryoport, Inc. (0001124524) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
- INSIDERSEC Form 4 filed by Stefanovich Robert4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERSEC Form 4 filed by Shelton Jerrell4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERSEC Form 4 filed by Sawicki Mark W4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDEROfficer Zecchini Edward J was granted 21,322 shares and sold $16,112 worth of shares (2,014 units at $8.00), increasing direct ownership by 21% to 109,719 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERPresident, CEO Shelton Jerrell sold $63,344 worth of shares (7,918 units at $8.00), decreasing direct ownership by 0.75% to 1,054,501 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERChief Scientific Officer Sawicki Mark W was granted 22,845 shares and sold $25,880 worth of shares (3,235 units at $8.00), increasing direct ownership by 23% to 103,697 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- INSIDERChief Financial Officer Stefanovich Robert exercised 87,188 shares at a strike of $1.87, sold $322,330 worth of shares (41,443 units at $7.78) and was granted 27,413 shares, increasing direct ownership by 35% to 280,371 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECSEC Form 144 filed by CryoPort Inc.144 - Cryoport, Inc. (0001124524) (Subject)
- SECSEC Form 10-K filed by CryoPort Inc.10-K - Cryoport, Inc. (0001124524) (Filer)
- SECCryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cryoport, Inc. (0001124524) (Filer)
- PRCryoport Reports Fourth Quarter and Full-Year 2025 Financial ResultsFY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
- PRCryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd
- PRCryoport's MVE Biological Solutions Introduces New Fusion® 800 SeriesSelf-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designe
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
- INSIDERDirector Mandalam Ramkumar sold $115,540 worth of shares (11,570 units at $9.99), decreasing direct ownership by 13% to 80,758 units (SEC Form 4)4 - Cryoport, Inc. (0001124524) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
- SECSEC Form 10-Q filed by CryoPort Inc.10-Q - Cryoport, Inc. (0001124524) (Filer)
- PRCryoport Systems Wins 2025 BioTech Breakthrough Award For "BioServices Innovation of the Year"LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced that Cryoport Systems, a subsidiary of Cryoport, Inc. (NASDAQ:CYRX), a leader in temperature-controlled supply chain solutions for the Life Sciences with a focus on regenerative medicine, today announced the Safepak® Soft System 1800 has been selected as "BioServices Innovation of the Year" in the fifth annual BioTech Breakthrough Awards program. The Safepak Soft System 1800 is a secondary packaging solution that combines proprieta